Clearside Biomedical, Inc. announced that it will conduct a randomized, controlled, double-masked, Phase 2b clinical trial, called ODYSSEY, in wet AMD participants. Based on the draft guidance on wet AMD drug development released on February 24, 2023, by the U.S. Food & Drug Administration (FDA), plan to adjust trial design to use on-label aflibercept dosing in the comparator arm of ODYSSEY. The company expects a seamless transition to this adjusted trial design and plan to open trial enrollment in the second quarter of 2023.